Your browser doesn't support javascript.
loading
Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.
Verma, Vivek; Shostrom, Valerie K; Zhen, Weining; Zhang, Mutian; Braunstein, Steve E; Holland, John; Hallemeier, Christopher L; Harkenrider, Matthew M; Iskhanian, Adrian; Jabbour, Salma K; Attia, Albert; Lee, Percy; Wang, Kyle; Decker, Roy H; McGarry, Ronald C; Simone, Charles B.
Afiliación
  • Verma V; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Shostrom VK; Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska.
  • Zhen W; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Zhang M; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Braunstein SE; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
  • Holland J; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon.
  • Hallemeier CL; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
  • Harkenrider MM; Department of Radiation Oncology, Loyola University Stritch School of Medicine, Maywood, Illinois.
  • Iskhanian A; Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida.
  • Jabbour SK; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.
  • Attia A; Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Lee P; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Wang K; Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Decker RH; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
  • McGarry RC; Department of Radiation Oncology, University of Kentucky, Lexington, Kentucky.
  • Simone CB; Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland. Electronic address: charlessimone@umm.edu.
Int J Radiat Oncol Biol Phys ; 97(4): 778-785, 2017 03 15.
Article en En | MEDLINE | ID: mdl-28244414
ABSTRACT

PURPOSE:

To describe the impact of fractionation scheme and tumor location on toxicities in stereotactic body radiation therapy (SBRT) for ≥5-cm non-small cell lung cancer (NSCLC), as part of a multi-institutional analysis.

METHODS:

Patients with primary ≥5-cm N0 M0 NSCLC who underwent ≤5-fraction SBRT were examined across multiple high-volume SBRT centers. Collected data included clinical/treatment parameters; toxicities were prospectively assessed at each institution according to the Common Terminology Criteria for Adverse Events. Patients treated daily were compared with those treated every other day (QOD)/other nondaily regimens. Stratification between central and peripheral tumors was also performed.

RESULTS:

Ninety-two patients from 12 institutions were evaluated (2004-2016), with median follow-up of 12 months. In total there were 23 (25%) and 6 (7%) grade ≥2 and grade ≥3 toxicities, respectively. Grades 2 and 3 pulmonary toxicities occurred in 9% and 4%, respectively; 1 patient treated daily experienced grade 5 radiation pneumonitis. Of the entire cohort, 46 patients underwent daily SBRT, and 46 received QOD (n=40)/other nondaily (n=6) regimens. Clinical/treatment parameters were similar between groups; the QOD/other group was more likely to receive 3-/4-fraction schemas. Patients treated QOD/other experienced significantly fewer grade ≥2 toxicities as compared with daily treatment (7% vs 43%, P<.001). Patients treated daily also had higher rates of grade ≥2 pulmonary toxicities (P=.014). Patients with peripheral tumors (n=66) were more likely to receive 3-/4-fraction regimens than those with central tumors (n=26). No significant differences in grade ≥2 toxicities were identified according to tumor location (P>.05).

CONCLUSIONS:

From this multi-institutional study, toxicity of SBRT for ≥5-cm lesions is acceptable, and daily treatment was associated with a higher rate of toxicities.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neumonitis por Radiación / Carcinoma de Pulmón de Células no Pequeñas / Fraccionamiento de la Dosis de Radiación / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neumonitis por Radiación / Carcinoma de Pulmón de Células no Pequeñas / Fraccionamiento de la Dosis de Radiación / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2017 Tipo del documento: Article